Matches in Wikidata for { <http://www.wikidata.org/entity/Q61917834> ?p ?o ?g. }
Showing items 1 to 47 of
47
with 100 items per page.
- Q61917834 description "assaig clínic" @default.
- Q61917834 description "clinical trial" @default.
- Q61917834 description "clinical trial" @default.
- Q61917834 description "clinical trial" @default.
- Q61917834 description "clinical trial" @default.
- Q61917834 description "ensaio clínico" @default.
- Q61917834 description "ensayo clínico" @default.
- Q61917834 description "ensayu clínicu" @default.
- Q61917834 description "essai clinique" @default.
- Q61917834 description "klinisch onderzoek" @default.
- Q61917834 description "клінічне випробування" @default.
- Q61917834 name "Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy" @default.
- Q61917834 type Item @default.
- Q61917834 label "Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy" @default.
- Q61917834 prefLabel "Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy" @default.
- Q61917834 P1050 Q61917834-758C21D8-4D35-4957-8108-674F906C38AA @default.
- Q61917834 P1050 Q61917834-D9854D1D-A677-4860-92CD-7C01AF8A252B @default.
- Q61917834 P1132 Q61917834-322E0E21-9D80-4473-B0F1-4E8672FE68AA @default.
- Q61917834 P1476 Q61917834-3ADAF58B-C54B-4883-A453-08DBA5F98805 @default.
- Q61917834 P17 Q61917834-A014A6CF-4769-4AD4-9F50-B9262D273747 @default.
- Q61917834 P1813 Q61917834-3D79382B-4465-477C-9F3C-C7B71FF22C1E @default.
- Q61917834 P2899 Q61917834-1E49177A-601E-4179-9BE7-7125414BBD6D @default.
- Q61917834 P3098 Q61917834-00766662-9637-4FDC-8A45-B0DE682FA082 @default.
- Q61917834 P31 Q61917834-B4A621B3-3B90-4B32-881B-C3700D4BF8AF @default.
- Q61917834 P4135 Q61917834-559BB5A1-E244-4F7D-A31F-DA42A694C335 @default.
- Q61917834 P4844 Q61917834-1C2151FB-9523-4958-BD04-CEA5008E07E3 @default.
- Q61917834 P580 Q61917834-BA7D03A1-1292-4026-8B43-7E371EFABE9B @default.
- Q61917834 P582 Q61917834-39C54390-C424-4E16-8B5A-40F1960C1C67 @default.
- Q61917834 P6099 Q61917834-E3FEFDF0-5211-4CF4-92D2-5A16FABBC99E @default.
- Q61917834 P8363 Q61917834-42BAB9A0-3F22-4E56-9DFD-C0C9E62042AA @default.
- Q61917834 P921 Q61917834-B9AFA429-CE55-43E0-BDA3-C66954295B3F @default.
- Q61917834 P1050 Q140067 @default.
- Q61917834 P1050 Q8277 @default.
- Q61917834 P1132 "+3" @default.
- Q61917834 P1476 "A Swedish Multi-Centre, Prospective, Open Label Study: Safety of Avonex Treatment in Multiple Sclerosis Patients Who Are NAB Positive on Previous s.c Interferon Beta Therapy" @default.
- Q61917834 P17 Q34 @default.
- Q61917834 P1813 "SAFE" @default.
- Q61917834 P2899 "+18" @default.
- Q61917834 P3098 "NCT00493077" @default.
- Q61917834 P31 Q30612 @default.
- Q61917834 P4135 "+55" @default.
- Q61917834 P4844 Q2450337 @default.
- Q61917834 P580 "2004-05-01T00:00:00Z" @default.
- Q61917834 P582 "2006-05-01T00:00:00Z" @default.
- Q61917834 P6099 Q42825046 @default.
- Q61917834 P8363 Q78089383 @default.
- Q61917834 P921 Q10566551 @default.